| 10001 | Other haemoglobinopathies | FING00001053 | 3.81e-04 |
| 10002 | TGFBR3 levels | GCST90470848 | 3.79e-04 |
| 10003 | CNTNAP4 levels | GCST90468809 | 3.79e-04 |
| 10004 | Oral glucose tolerance test-0h | GCST90297788 | 3.79e-04 |
| 10005 | GNLY levels | GCST90469372 | 3.79e-04 |
| 10006 | Nephrotic syndrome | GCST90018664 | 3.78e-04 |
| 10007 | CD14 levels | GCST90468598 | 3.78e-04 |
| 10008 | Lysophosphatidylcholine (24:0) [sn1] levels | GCST90025425 | 3.78e-04 |
| 10009 | NUB1/SRPK2 ratio | GCST90315573 | 3.77e-04 |
| 10010 | Saturated fatty acids to total fatty acids percentage | GCST90502697 | 3.77e-04 |
| 10011 | CCL2 levels | GCST90468581 | 3.77e-04 |
| 10012 | ERN1 levels | GCST90469148 | 3.77e-04 |
| 10013 | AMBP/RARRES2 ratio | GCST90313256 | 3.76e-04 |
| 10014 | IDP dMRI ProbtrackX ISOVF str r | GCST90004549 | 3.76e-04 |
| 10015 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T24 | ECGU000024 | 3.76e-04 |
| 10016 | SPINK4 levels | GCST90470723 | 3.76e-04 |
| 10017 | ADIPOQ levels | GCST90293086 | 3.75e-04 |
| 10018 | ADGRE5 levels | GCST90425484 | 3.74e-04 |
| 10019 | Bladder stone | GCST90468116 | 3.74e-04 |
| 10020 | ART3 levels | GCST90468370 | 3.74e-04 |
| 10021 | NCK2 levels | GCST90470007 | 3.74e-04 |
| 10022 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T465 | ECGU000465 | 3.74e-04 |
| 10023 | ABHD14B/CCS ratio | GCST90313139 | 3.74e-04 |
| 10024 | SUGT1 levels | GCST90470780 | 3.74e-04 |
| 10025 | PPP1R12A/SPARC ratio | GCST90315712 | 3.73e-04 |
| 10026 | SH2D1A levels | GCST90470617 | 3.73e-04 |
| 10027 | C4BPB/ENTPD5 ratio | GCST90313556 | 3.72e-04 |
| 10028 | Phospholipids in very small VLDL (UKB data field 23518) | GCST90269615 | 3.72e-04 |
| 10029 | CIAPIN1 levels | GCST90468753 | 3.71e-04 |
| 10030 | CCN2/MGLL ratio | GCST90313714 | 3.68e-04 |
| 10031 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T105 | ECGU000105 | 3.66e-04 |
| 10032 | EFNA4/TNFRSF10B ratio | GCST90314605 | 3.65e-04 |
| 10033 | Coronary atherosclerosis (PheCode 411.4) | GCST90043957 | 3.65e-04 |
| 10034 | FUOM levels | GCST90469276 | 3.65e-04 |
| 10035 | CLPS/CTRB1 ratio | GCST90314139 | 3.65e-04 |
| 10036 | Free androgen index | GCST90239824 | 3.65e-04 |
| 10037 | TBCB levels | GCST90470813 | 3.65e-04 |
| 10038 | EGF/PPIB ratio | GCST90314612 | 3.64e-04 |
| 10039 | Deoxycholic acid glucuronide metabolite level | GCST90616229 | 3.63e-04 |
| 10040 | REST UKBBICA NODEamps25 0016 | GCST90385499 | 3.63e-04 |
| 10041 | CXCL6/DFFA ratio | GCST90314357 | 3.62e-04 |
| 10042 | EEF1D levels | GCST90469075 | 3.61e-04 |
| 10043 | Triglycerides to Total Lipids in Small VLDL percentage | GCST90499922 | 3.61e-04 |
| 10044 | FOXO1/NUB1 ratio | GCST90314874 | 3.60e-04 |
| 10045 | Phospholipids to Total Lipids in Small HDL percentage | GCST90499494 | 3.59e-04 |
| 10046 | Benign lipomatous neoplasm | FING00000146 | 3.59e-04 |
| 10047 | LRCH4 levels | GCST90469791 | 3.59e-04 |
| 10048 | CBLN4 levels | GCST90468554 | 3.59e-04 |
| 10049 | aparc-a2009s rh volume G+S-subcentral | GCST90003002 | 3.58e-04 |
| 10050 | GGH levels | GCST90469335 | 3.58e-04 |
| 10051 | DNAJA2/PRDX5 ratio | GCST90314506 | 3.58e-04 |
| 10052 | End-diastolic bi-ventricular shape (principal component 1) | GCST90448480 | 3.58e-04 |
| 10053 | FCRL1/TNFRSF13C ratio | GCST90314796 | 3.56e-04 |
| 10054 | Total Phosphatidylethanolamine levels | GCST90025207 | 3.56e-04 |
| 10055 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 3.55e-04 |
| 10056 | Phosphatidylethanolamine_40:6_[M-H]1- levels | GCST90060365 | 3.54e-04 |
| 10057 | DSG3/FABP9 ratio | GCST90314559 | 3.54e-04 |
| 10058 | STROKE | FING00001336 | 3.54e-04 |
| 10059 | Cholesteryl ester levels in small HDL | GCST90092946 | 3.54e-04 |
| 10060 | TNFRSF14/TNFRSF1A ratio | GCST90315935 | 3.54e-04 |
| 10061 | DSG4/FABP9 ratio | GCST90314562 | 3.53e-04 |
| 10062 | Linoleic acid to total fatty acids percentage | GCST90502023 | 3.53e-04 |
| 10063 | Phosphatidylcholine-O_34:3_[M+H]1+/Phosphatidylcholine-P_34:2_[M+H]1+/Phosphatidylethanolamine-P_37:2_[M+H]1+ levels | GCST90060277 | 3.52e-04 |
| 10064 | Gestational thrombocytopenia | GCST90302234 | 3.50e-04 |
| 10065 | NAAA levels | GCST90469991 | 3.50e-04 |
| 10066 | Concentration of HDL particles | GCST90497406 | 3.50e-04 |
| 10067 | CD3 on Terminally Differentiated CD4+ T cell | GCST90001844 | 3.49e-04 |
| 10068 | CCL14/CST3 ratio | GCST90313679 | 3.49e-04 |
| 10069 | NUB1 levels | GCST90470099 | 3.49e-04 |
| 10070 | TNFSF14 levels | GCST90470922 | 3.49e-04 |
| 10071 | Phospholipids in very large HDL | GCST90500451 | 3.48e-04 |
| 10072 | Glomerular filtration rate (creatinine) | GCST003372 | 3.47e-04 |
| 10073 | Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646) | GCST90269743 | 3.47e-04 |
| 10074 | Acute osteomyelitis (PheCode 710.11) | GCST90476222 | 3.47e-04 |
| 10075 | SGSH levels | GCST90470615 | 3.47e-04 |
| 10076 | HHEX levels | GCST90469451 | 3.46e-04 |
| 10077 | SMPDL3A levels | GCST90470686 | 3.46e-04 |
| 10078 | Snoring | GCST009761 | 3.45e-04 |
| 10079 | DTI autoptx MD cgc l tract | GCST90385224 | 3.45e-04 |
| 10080 | ITGB1BP2/PTPN6 ratio | GCST90315218 | 3.42e-04 |
| 10081 | GP6/LGALS8 ratio | GCST90314964 | 3.41e-04 |
| 10082 | DAG1/PDGFB ratio | GCST90314379 | 3.40e-04 |
| 10083 | IL6 levels | GCST90469604 | 3.40e-04 |
| 10084 | LILRA5 levels | GCST90469774 | 3.40e-04 |
| 10085 | Hypoplasia of dental enamel, including avohilmo | FING00000652 | 3.40e-04 |
| 10086 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320665 | 3.39e-04 |
| 10087 | EPHA2 levels | GCST90469130 | 3.39e-04 |
| 10088 | TMSB10/TRIAP1 ratio | GCST90315924 | 3.39e-04 |
| 10089 | Cholesteryl Esters in IDL | GCST90497523 | 3.39e-04 |
| 10090 | DTI autoptx MD ilf l tract | GCST90385234 | 3.38e-04 |
| 10091 | DECR1 levels | GCST90468978 | 3.38e-04 |
| 10092 | GALNT2 levels | GCST90469296 | 3.38e-04 |
| 10093 | SOST/SPP1 ratio | GCST90315871 | 3.37e-04 |
| 10094 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500866 | 3.36e-04 |
| 10095 | Heel quantitative ultrasound index (QUI), direct entry | Bone-densitometry of heel | UKBB00000324 | 3.36e-04 |
| 10096 | CCL15 levels | GCST90468567 | 3.36e-04 |
| 10097 | Heel bone mineral density (BMD) T-score, automated | Bone-densitometry of heel | UKBB00000318 | 3.36e-04 |
| 10098 | Asthma | GCST90018575 | 3.35e-04 |
| 10099 | DTI TBSS L2 Posterior thalamic radiation R | GCST90384504 | 3.35e-04 |
| 10100 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502373 | 3.35e-04 |
| 10101 | Heel bone mineral density (BMD) | Bone-densitometry of heel | UKBB00000315 | 3.35e-04 |
| 10102 | LBR/POLR2F ratio | GCST90315297 | 3.35e-04 |
| 10103 | GSTA3 levels | GCST90469412 | 3.35e-04 |
| 10104 | CHL1 levels | GCST90468745 | 3.34e-04 |
| 10105 | F11R/PLXNA4 ratio | GCST90314724 | 3.34e-04 |
| 10106 | SLITRK2 levels | GCST90470670 | 3.33e-04 |
| 10107 | IDP dMRI TBSS OD Posterior corona radiata R | GCST90004428 | 3.33e-04 |
| 10108 | Heel Broadband ultrasound attenuation, direct entry | Bone-densitometry of heel | UKBB00000321 | 3.33e-04 |
| 10109 | aparc-DKTatlas lh area superiorparietal | GCST90003261 | 3.33e-04 |
| 10110 | DNAJB1/STIP1 ratio | GCST90314513 | 3.33e-04 |
| 10111 | Treatment or medication use - atorvastatin (UKB data field 20003_1141146234) | GCST90042376 | 3.32e-04 |
| 10112 | PODXL2/SEZ6L ratio | GCST90315702 | 3.31e-04 |
| 10113 | KLK8/LY6D ratio | GCST90315257 | 3.31e-04 |
| 10114 | HBEGF/YES1 ratio | GCST90315039 | 3.31e-04 |
| 10115 | SCN4B levels | GCST90470551 | 3.30e-04 |
| 10116 | Suppurative and unspecified otitis media | FING00001346 | 3.29e-04 |
| 10117 | IDP dMRI TBSS ICVF Cerebral peduncle L | GCST90004342 | 3.29e-04 |
| 10118 | MBL2 levels | GCST90469868 | 3.27e-04 |
| 10119 | ARHGEF1 levels | GCST90468359 | 3.27e-04 |
| 10120 | FGF21 levels | GCST90274788 | 3.27e-04 |
| 10121 | OMG levels | GCST90470124 | 3.26e-04 |
| 10122 | HippSubfield lh volume CA4-body | GCST90002683 | 3.26e-04 |
| 10123 | Allergic rhinitis | GCST90086042 | 3.26e-04 |
| 10124 | Alanine transaminase (ALT, maximum, inv-norm transformed) | GCST90475109 | 3.25e-04 |
| 10125 | DLL1/NBL1 ratio | GCST90314496 | 3.24e-04 |
| 10126 | Transient global amnesia | FING00001374 | 3.24e-04 |
| 10127 | Forearm length to body height ratio | GCST90270257 | 3.24e-04 |
| 10128 | BSG/CKAP4 ratio | GCST90313531 | 3.23e-04 |
| 10129 | ASGR2 levels | GCST90468376 | 3.23e-04 |
| 10130 | Type 2 diabetes | GCST005413 | 3.22e-04 |
| 10131 | Platelet count | GCST90018749 | 3.22e-04 |
| 10132 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T226 | ECGU000226 | 3.20e-04 |
| 10133 | Saturated fatty acids to total fatty acids percentage (UKB data field 23455) | GCST90269552 | 3.19e-04 |
| 10134 | PLEKHO1 levels | GCST90470256 | 3.18e-04 |
| 10135 | FAS levels | GCST90469192 | 3.17e-04 |
| 10136 | Cholesterol in medium HDL (UKB data field 23568) | GCST90269665 | 3.16e-04 |
| 10137 | SMOC2 levels | GCST90470683 | 3.16e-04 |
| 10138 | A body shape index | GCST90020024 | 3.15e-04 |
| 10139 | BRAP levels | GCST90468464 | 3.14e-04 |
| 10140 | FHIT/PMVK ratio | GCST90314822 | 3.12e-04 |
| 10141 | Cholesteryl Esters to Total Lipids in Small HDL percentage | GCST90499403 | 3.11e-04 |
| 10142 | Cholesteryl esters in small HDL (UKB data field 23576) | GCST90269673 | 3.10e-04 |
| 10143 | Mean corpuscular hemoglobin concentration | GCST004605 | 3.10e-04 |
| 10144 | PDGFA/PLA2G4A ratio | GCST90315615 | 3.09e-04 |
| 10145 | CXCL11/SDC4 ratio | GCST90314336 | 3.08e-04 |
| 10146 | rfMRI amplitudes (ICA25 node 14) | GCST90004581 | 3.08e-04 |
| 10147 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 3.07e-04 |
| 10148 | Sphingomyelin_38:2_[M+H]1+ levels | GCST90060302 | 3.07e-04 |
| 10149 | PDGFRA levels | GCST90470191 | 3.06e-04 |
| 10150 | ADAMTS13 levels | GCST90468222 | 3.06e-04 |
| 10151 | XG levels | GCST90471082 | 3.05e-04 |
| 10152 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T92 | ECGU000092 | 3.05e-04 |
| 10153 | FXN levels | GCST90469282 | 3.04e-04 |
| 10154 | FGF23 levels | GCST90469223 | 3.03e-04 |
| 10155 | MATN2/SCARA5 ratio | GCST90315388 | 3.03e-04 |
| 10156 | Total concentration of lipoprotein particles | GCST90500103 | 3.02e-04 |
| 10157 | VSTM1 levels | GCST90471055 | 3.02e-04 |
| 10158 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T114 | ECGA000114 | 3.01e-04 |
| 10159 | DAAM1 levels | GCST90468941 | 3.01e-04 |
| 10160 | IGFBP4 levels | GCST90469530 | 3.00e-04 |
| 10161 | Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093051 | 3.00e-04 |
| 10162 | Mean bone marrow fat fraction of left and right proximal femur | GCST90652394 | 2.99e-04 |
| 10163 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499369 | 2.99e-04 |
| 10164 | ICA1/TANK ratio | GCST90315112 | 2.98e-04 |
| 10165 | Neutrophil percentage of white cells variance | GCST90565701 | 2.98e-04 |
| 10166 | Falls/tendency to fall | FING00000530 | 2.98e-04 |
| 10167 | DSG3 levels | GCST90469043 | 2.97e-04 |
| 10168 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) | GCST90499340 | 2.96e-04 |
| 10169 | CALCA levels | GCST90468528 | 2.96e-04 |
| 10170 | SARG levels | GCST90470526 | 2.96e-04 |
| 10171 | NCR1 levels | GCST90470009 | 2.96e-04 |
| 10172 | MESD levels | GCST90469891 | 2.96e-04 |
| 10173 | Diastolic blood pressure x sex interaction | GCST90335175 | 2.96e-04 |
| 10174 | BOC levels | GCST90468458 | 2.93e-04 |
| 10175 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T487 | ECGU000487 | 2.93e-04 |
| 10176 | Monounsaturated fatty acid levels | GCST90502030 | 2.92e-04 |
| 10177 | PRKAR2A levels | GCST90470327 | 2.92e-04 |
| 10178 | GPC1/ITGB6 ratio | GCST90314977 | 2.92e-04 |
| 10179 | Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels | GCST90200098 | 2.91e-04 |
| 10180 | FABP5/PPCDC ratio | GCST90314763 | 2.91e-04 |
| 10181 | PTPRF/SDC1 ratio | GCST90315752 | 2.91e-04 |
| 10182 | Volume of right cortical nucleus | GCST90475033 | 2.91e-04 |
| 10183 | Immature reticulocyte fraction | Blood count | UKBB00000355 | 2.90e-04 |
| 10184 | Metabolic disorder, other/unspecified | FING00000815 | 2.89e-04 |
| 10185 | Abdominal aortic aneurysm (PheCode 442.11) | GCST90475994 | 2.89e-04 |
| 10186 | Linoleic acid to total fatty acids percentage | GCST90502333 | 2.88e-04 |
| 10187 | TNFRSF12A levels | GCST90470904 | 2.88e-04 |
| 10188 | Linoleic acid to total fatty acids percentage | GCST90498321 | 2.87e-04 |
| 10189 | CXCL10/WARS ratio | GCST90314332 | 2.87e-04 |
| 10190 | CPE levels | GCST90468841 | 2.87e-04 |
| 10191 | CC2D1A/TMSB10 ratio | GCST90313667 | 2.87e-04 |
| 10192 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502397 | 2.86e-04 |
| 10193 | CTSC levels | GCST90468909 | 2.85e-04 |
| 10194 | CDH5/NOTCH1 ratio | GCST90313957 | 2.85e-04 |
| 10195 | DTD1 levels | GCST90469045 | 2.84e-04 |
| 10196 | Concentration of large VLDL particles | GCST90498223 | 2.83e-04 |
| 10197 | HTRA2/TRIAP1 ratio | GCST90315099 | 2.82e-04 |
| 10198 | DAPP1/SDC4 ratio | GCST90314399 | 2.82e-04 |
| 10199 | CDH5/TEK ratio | GCST90313961 | 2.82e-04 |
| 10200 | ADAM12 levels | GCST90468216 | 2.82e-04 |
| 10201 | Saturated fatty acids levels | GCST90502674 | 2.81e-04 |
| 10202 | GKN1 levels | GCST90469353 | 2.81e-04 |
| 10203 | PCDH7 levels | GCST90470171 | 2.80e-04 |
| 10204 | PDGFB/PPP1R12A ratio | GCST90315623 | 2.80e-04 |
| 10205 | MSTN/RGMA ratio | GCST90315504 | 2.80e-04 |
| 10206 | Ptosis of eyelid | FING00001227 | 2.79e-04 |
| 10207 | ASRGL1 levels | GCST90468379 | 2.78e-04 |
| 10208 | Eosinophil percentage of white cells variance | GCST90565690 | 2.78e-04 |
| 10209 | Rosacea (PheCode 695.3) | GCST90476178 | 2.78e-04 |
| 10210 | PLA2G4A/SDC4 ratio | GCST90315668 | 2.77e-04 |
| 10211 | IDP dMRI TBSS OD Genu of corpus callosum | GCST90004404 | 2.77e-04 |
| 10212 | SERPINF1 levels | GCST90470598 | 2.77e-04 |
| 10213 | IDP T1 FAST ROIs L subcallosal cortex | GCST90002503 | 2.77e-04 |
| 10214 | SIGLEC7 levels | GCST90470635 | 2.77e-04 |
| 10215 | CRNN levels | GCST90468869 | 2.77e-04 |
| 10216 | Pulmonary embolism | FING00001228 | 2.77e-04 |
| 10217 | Creatinine levels (UKB data field 23478) | GCST90269575 | 2.76e-04 |
| 10218 | CD226 levels | GCST90468609 | 2.76e-04 |
| 10219 | Triglycerides to Total Lipids in IDL percentage | GCST90497676 | 2.75e-04 |
| 10220 | Status post-ami | FING00001333 | 2.75e-04 |
| 10221 | Lung cancer | GCST004748 | 2.75e-04 |
| 10222 | Phospholipids in very small VLDL | GCST90500851 | 2.75e-04 |
| 10223 | Hypertensive chronic kidney disease (PheCode 401.22) | GCST90475927 | 2.74e-04 |
| 10224 | VNN1 levels | GCST90471043 | 2.74e-04 |
| 10225 | Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626) | GCST90269723 | 2.74e-04 |
| 10226 | Operation code - inguinal hernia repair | Operations | UKBB00000560 | 2.73e-04 |
| 10227 | T1 FreeSurfer DKT lh lateraloccipital area | GCST90384202 | 2.73e-04 |
| 10228 | LPL levels | GCST90469788 | 2.73e-04 |
| 10229 | MIA/NBL1 ratio | GCST90315445 | 2.72e-04 |
| 10230 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 2.71e-04 |
| 10231 | CEP43/USP8 ratio | GCST90314022 | 2.71e-04 |
| 10232 | UMOD levels | GCST90471009 | 2.71e-04 |
| 10233 | CDKN1A/DAB2 ratio | GCST90313967 | 2.69e-04 |
| 10234 | Conduction disorders | FING00000324 | 2.69e-04 |
| 10235 | SNAP29/SNX9 ratio | GCST90315859 | 2.69e-04 |
| 10236 | BTN2A1/IFNGR1 ratio | GCST90313543 | 2.69e-04 |
| 10237 | Degree of unsaturation | GCST90502746 | 2.69e-04 |
| 10238 | FUT8/TNFSF12 ratio | GCST90314894 | 2.68e-04 |
| 10239 | HAVCR1 levels | GCST90012041 | 2.68e-04 |
| 10240 | Red blood cell count | GCST004601 | 2.68e-04 |
| 10241 | TRAF3 levels | GCST90470957 | 2.67e-04 |
| 10242 | DTI autoptx L3 unc l tract | GCST90385218 | 2.66e-04 |
| 10243 | Benign neoplasm of colon, rectum, anus and anal canal | Benign neoplasms | UKBB00000093 | 2.65e-04 |
| 10244 | Serum phosphate levels | GCST90025948 | 2.65e-04 |
| 10245 | Total Lipids in HDL | GCST90497393 | 2.65e-04 |
| 10246 | CST3/TIMP1 ratio | GCST90314300 | 2.64e-04 |
| 10247 | S100A4 levels | GCST90470518 | 2.64e-04 |
| 10248 | PLA2G2A levels | GCST90470247 | 2.64e-04 |
| 10249 | Lymphocyte count | GCST90018742 | 2.63e-04 |
| 10250 | CD58/IFNGR1 ratio | GCST90313849 | 2.63e-04 |
| 10251 | BCAM/EPO ratio | GCST90313471 | 2.61e-04 |
| 10252 | PIBF1 levels | GCST90470231 | 2.60e-04 |
| 10253 | Pollinosis | GCST90018683 | 2.60e-04 |
| 10254 | FGFR2/TGFBR2 ratio | GCST90314813 | 2.59e-04 |
| 10255 | PTPN6/SNAP23 ratio | GCST90315747 | 2.59e-04 |
| 10256 | PILRA levels | GCST90470236 | 2.59e-04 |
| 10257 | COMMD1 levels | GCST90468825 | 2.59e-04 |
| 10258 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T59 | ECGA000059 | 2.58e-04 |
| 10259 | LPP levels | GCST90469790 | 2.58e-04 |
| 10260 | CD300E/CD59 ratio | GCST90313794 | 2.57e-04 |
| 10261 | SERPINB1/SERPINB6 ratio | GCST90315826 | 2.56e-04 |
| 10262 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T26 | ECGU000026 | 2.56e-04 |
| 10263 | MAVS/RNF41 ratio | GCST90315395 | 2.56e-04 |
| 10264 | CCL3 levels | GCST90468582 | 2.56e-04 |
| 10265 | DSG3/SPINK5 ratio | GCST90314561 | 2.55e-04 |
| 10266 | BAP18 levels | GCST90468422 | 2.55e-04 |
| 10267 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T56 | ECGA000056 | 2.54e-04 |
| 10268 | VCAM1 levels | GCST90243317 | 2.53e-04 |
| 10269 | ST3GAL1 levels | GCST90470752 | 2.53e-04 |
| 10270 | SRC levels | GCST90470741 | 2.52e-04 |
| 10271 | CTRB1/PLA2G1B ratio | GCST90314307 | 2.52e-04 |
| 10272 | SKAP2/VSIR ratio | GCST90315849 | 2.51e-04 |
| 10273 | AHSP/HMBS ratio | GCST90313217 | 2.50e-04 |
| 10274 | CD8 on Effector Memory CD8+ T cell | GCST90002056 | 2.50e-04 |
| 10275 | CD79B levels | GCST90468648 | 2.49e-04 |
| 10276 | IDP dMRI TBSS MO Fornix | GCST90003957 | 2.49e-04 |
| 10277 | Triglyceride levels in HDL | GCST90092829 | 2.48e-04 |
| 10278 | Hard cardiovascular diseases | FING00000602 | 2.47e-04 |
| 10279 | Phospholipids in small HDL | GCST90499478 | 2.47e-04 |
| 10280 | Other venous embolism and thrombosis (PheCode 452) | GCST90476007 | 2.47e-04 |
| 10281 | Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74) | GCST90668518 | 2.47e-04 |
| 10282 | Carotid intima-media thickness (MTAG) | GCST90449061 | 2.46e-04 |
| 10283 | Otitis externa, unspecified | FING00001129 | 2.46e-04 |
| 10284 | TACC3/TBC1D23 ratio | GCST90315900 | 2.46e-04 |
| 10285 | Platelet count (UKB data field 30080) | GCST90468095 | 2.46e-04 |
| 10286 | Urea | Blood biochemistry | UKBB00000885 | 2.45e-04 |
| 10287 | DTI autoptx FA ifo r tract | GCST90385125 | 2.45e-04 |
| 10288 | Osteoporosis | musculoskeletal | UKBB00000598 | 2.45e-04 |
| 10289 | APOL1 levels | GCST90468341 | 2.45e-04 |
| 10290 | X-12411 levels | GCST90200492 | 2.44e-04 |
| 10291 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T95 | ECGU000095 | 2.44e-04 |
| 10292 | MZB1/TNFRSF13B ratio | GCST90315509 | 2.43e-04 |
| 10293 | Heel bone mineral density | GCST006288 | 2.43e-04 |
| 10294 | GP2/LGALS8 ratio | GCST90314961 | 2.42e-04 |
| 10295 | Triglycerides in large VLDL | GCST90498267 | 2.42e-04 |
| 10296 | BCL2L1 levels | GCST90468432 | 2.42e-04 |
| 10297 | Posterior diffusion tensor imaging along the perivascular space index | GCST90455545 | 2.42e-04 |
| 10298 | Bifidobacterium kashiwanohense abundance in stool | GCST90032226 | 2.41e-04 |
| 10299 | NRSN1 levels | GCST90242062 | 2.40e-04 |
| 10300 | ITGA5/LILRA2 ratio | GCST90315204 | 2.40e-04 |
| 10301 | Lymphocyte count | GCST90002388 | 2.39e-04 |
| 10302 | DTI autoptx L3 ilf l tract | GCST90385207 | 2.39e-04 |
| 10303 | CNTN4 levels | GCST90468806 | 2.39e-04 |
| 10304 | Takes medication for peripheral vascular disease? | GCST90475220 | 2.39e-04 |
| 10305 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498516 | 2.39e-04 |
| 10306 | CR2/TNFRSF13B ratio | GCST90314225 | 2.38e-04 |
| 10307 | CX3CL1/EPHB6 ratio | GCST90314324 | 2.38e-04 |
| 10308 | N-formylanthranilic acid levels | GCST90199960 | 2.38e-04 |
| 10309 | NAA80 levels | GCST90469990 | 2.37e-04 |
| 10310 | 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0) levels | GCST90200083 | 2.37e-04 |
| 10311 | CCL13/CCL8 ratio | GCST90313676 | 2.37e-04 |
| 10312 | IDP dMRI TBSS L1 Posterior corona radiata R | GCST90004101 | 2.37e-04 |
| 10313 | Concentration of very small VLDL particles | GCST90500826 | 2.36e-04 |
| 10314 | ESAM/THPO ratio | GCST90314719 | 2.36e-04 |
| 10315 | Immature fraction of reticulocytes | GCST90002387 | 2.36e-04 |
| 10316 | Medication use (glucocorticoids) | GCST90018780 | 2.35e-04 |
| 10317 | PRUNE2 levels | GCST90470349 | 2.35e-04 |
| 10318 | CASP10 levels | GCST90468542 | 2.35e-04 |
| 10319 | LILRB2 levels | GCST90469777 | 2.34e-04 |
| 10320 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T55 | ECGA000055 | 2.34e-04 |
| 10321 | ALB levels | GCST90475106 | 2.34e-04 |
| 10322 | MMP9 levels | GCST90469923 | 2.33e-04 |
| 10323 | Osteoarthritis; localized | musculoskeletal | UKBB00000595 | 2.33e-04 |
| 10324 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T101 | ECGA000101 | 2.33e-04 |
| 10325 | HSPG2/VASN ratio | GCST90315094 | 2.33e-04 |
| 10326 | EBAG9/TGFB1 ratio | GCST90314570 | 2.33e-04 |
| 10327 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T53 | ECGA000053 | 2.33e-04 |
| 10328 | Triglyceride levels | GCST90239663 | 2.32e-04 |
| 10329 | Total triglycerides levels | GCST90500126 | 2.32e-04 |
| 10330 | Hip index | GCST90020026 | 2.32e-04 |
| 10331 | CXCL13 levels | GCST90468926 | 2.32e-04 |
| 10332 | BA-exvivo lh area entorhinal | GCST90003220 | 2.32e-04 |
| 10333 | ADAMTSL5 levels | GCST90468230 | 2.30e-04 |
| 10334 | Plasma methylsuccinate levels in chronic kidney disease | GCST90265506 | 2.30e-04 |
| 10335 | CPB1/CTRB1 ratio | GCST90314208 | 2.30e-04 |
| 10336 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 119) | GCST90320938 | 2.29e-04 |
| 10337 | Phosphate levels (UKB data field 30810) | GCST90468094 | 2.29e-04 |
| 10338 | AMY1A or AMY1B or AMY1C levels | GCST90468297 | 2.28e-04 |
| 10339 | CD27/NECTIN4 ratio | GCST90313775 | 2.28e-04 |
| 10340 | DAB2/NCK2 ratio | GCST90314367 | 2.28e-04 |
| 10341 | Triglycerides to Total Lipids in Very Small VLDL percentage | GCST90500900 | 2.28e-04 |
| 10342 | PTPRS levels | GCST90470387 | 2.27e-04 |
| 10343 | Heart rate variability (root mean square of successive differences) | GCST90281263 | 2.27e-04 |
| 10344 | CCL4 levels | GCST90468583 | 2.27e-04 |
| 10345 | RGCC levels | GCST90470461 | 2.26e-04 |
| 10346 | RSPO1 levels | GCST90470503 | 2.26e-04 |
| 10347 | GFER/MAVS ratio | GCST90314919 | 2.26e-04 |
| 10348 | Coronary revascularization (ANGIO or CABG) | FING00000360 | 2.25e-04 |
| 10349 | Phospholipids in HDL | GCST90497437 | 2.25e-04 |
| 10350 | LY6D levels | GCST90469821 | 2.25e-04 |
| 10351 | HEXIM1/TRIAP1 ratio | GCST90315054 | 2.24e-04 |
| 10352 | Vitamin D levels | GCST005367 | 2.24e-04 |
| 10353 | EHBP1 levels | GCST90469088 | 2.24e-04 |
| 10354 | SNAP29/SPARC ratio | GCST90315860 | 2.23e-04 |
| 10355 | CHAC2 levels | GCST90468736 | 2.23e-04 |
| 10356 | OPTC levels | GCST90470128 | 2.23e-04 |
| 10357 | CD69/TXNDC5 ratio | GCST90313889 | 2.23e-04 |
| 10358 | IGF1 levels | UKBB00000337 | 2.22e-04 |
| 10359 | Bone marrow fat fraction of thoracic vertebra 9 | GCST90652381 | 2.22e-04 |
| 10360 | ARL13B levels | GCST90468363 | 2.22e-04 |
| 10361 | TRAF2/WWP2 ratio | GCST90315943 | 2.21e-04 |
| 10362 | SNAP29 levels | GCST90470692 | 2.21e-04 |
| 10363 | HSD11B1/SMPD1 ratio | GCST90315082 | 2.19e-04 |
| 10364 | APP/VEGFC ratio | GCST90313333 | 2.19e-04 |
| 10365 | NAGPA levels | GCST90469996 | 2.19e-04 |
| 10366 | ADGRF5 levels | GCST90468239 | 2.18e-04 |
| 10367 | FCRL2/LY9 ratio | GCST90314799 | 2.18e-04 |
| 10368 | A4GALT levels | GCST90427457 | 2.18e-04 |
| 10369 | IGF1 levels | GCST90102623 | 2.18e-04 |
| 10370 | CD300C/LRRC25 ratio | GCST90313790 | 2.17e-04 |
| 10371 | Osteoporosis NOS | musculoskeletal | UKBB00000599 | 2.17e-04 |
| 10372 | GET3 levels | GCST90469324 | 2.16e-04 |
| 10373 | Urine glucuronide of C10H18O2 (12)* levels in chronic kidney disease | GCST90265189 | 2.15e-04 |
| 10374 | CLEC3B levels | GCST90468770 | 2.15e-04 |
| 10375 | Cholesteryl Esters in Small HDL | GCST90499386 | 2.15e-04 |
| 10376 | IL22 levels | GCST90469582 | 2.15e-04 |
| 10377 | CLEC10A levels | GCST90468763 | 2.14e-04 |
| 10378 | CXCL17/SFTPA2 ratio | GCST90314341 | 2.13e-04 |
| 10379 | RGMA levels | GCST90470463 | 2.13e-04 |
| 10380 | VPS53 levels | GCST90471048 | 2.13e-04 |
| 10381 | NEXN levels | GCST90470030 | 2.12e-04 |
| 10382 | ENO2 levels | GCST90469110 | 2.12e-04 |
| 10383 | Cholesteryl esters in medium HDL (UKB data field 23569) | GCST90269666 | 2.12e-04 |
| 10384 | GBA1 levels | GCST90423262 | 2.11e-04 |
| 10385 | Phospholipids to total lipids ratio in IDL | GCST90092840 | 2.10e-04 |
| 10386 | KLKB1 levels | GCST90469708 | 2.09e-04 |
| 10387 | IL6ST/TYRO3 ratio | GCST90315170 | 2.09e-04 |
| 10388 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502068 | 2.09e-04 |
| 10389 | aseg rh volume Amygdala | GCST90002642 | 2.09e-04 |
| 10390 | EGF/MGLL ratio | GCST90314610 | 2.09e-04 |
| 10391 | BTN2A1/CSF1 ratio | GCST90313541 | 2.08e-04 |
| 10392 | CLEC5A levels | GCST90468776 | 2.08e-04 |
| 10393 | Cholesteryl Esters in Medium LDL | GCST90498739 | 2.08e-04 |
| 10394 | Concentration of medium HDL particles | GCST90498622 | 2.07e-04 |
| 10395 | IDP dMRI ProbtrackX ISOVF unc r | GCST90004551 | 2.07e-04 |
| 10396 | GFRA1/SPON2 ratio | GCST90314923 | 2.07e-04 |
| 10397 | EIF3J levels | GCST90241122 | 2.07e-04 |
| 10398 | FASLG levels | GCST90469191 | 2.06e-04 |
| 10399 | EIF4G1/NFATC1 ratio | GCST90314637 | 2.06e-04 |
| 10400 | Other degenerative diseases of the nervous system | FING00000994 | 2.06e-04 |
| 10401 | MGLL/PTPN6 ratio | GCST90315440 | 2.05e-04 |
| 10402 | Lymphocyte count | GCST90002317 | 2.05e-04 |
| 10403 | SERPINB8 levels | GCST90470592 | 2.05e-04 |
| 10404 | Phlebitis and thrombophlebitis of lower extremities (PheCode 451.2) | GCST90044025 | 2.05e-04 |
| 10405 | CCL22/TIMP3 ratio | GCST90313693 | 2.04e-04 |
| 10406 | CREG1/NAAA ratio | GCST90314250 | 2.04e-04 |
| 10407 | T1 FreeSurfer aseg MaskVol-to-eTIV | GCST90384192 | 2.04e-04 |
| 10408 | TPD52L2 levels | GCST90470942 | 2.04e-04 |
| 10409 | Calcific aortic valvular stenosis, operated | FING00000234 | 2.03e-04 |
| 10410 | COL2A1 levels | GCST90468816 | 2.03e-04 |
| 10411 | EPHB6/LAYN ratio | GCST90314681 | 2.03e-04 |
| 10412 | Prescriptions - lipase inhibitor|obesity | UKBB00000688 | 2.03e-04 |
| 10413 | Prescriptions - orlistat | lipase inhibitor,obesity | UKBB00000695 | 2.03e-04 |
| 10414 | STC2 levels | GCST90470762 | 2.02e-04 |
| 10415 | Other disorders of eyelid | FING00001026 | 2.02e-04 |
| 10416 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498556 | 2.02e-04 |
| 10417 | aparc-DKTatlas lh volume pericalcarine | GCST90002881 | 2.02e-04 |
| 10418 | LGALS1/LGALS8 ratio | GCST90315314 | 2.01e-04 |
| 10419 | AMBP/ASGR1 ratio | GCST90313251 | 2.01e-04 |
| 10420 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497906 | 2.01e-04 |
| 10421 | TGOLN2 levels | GCST90470850 | 2.01e-04 |
| 10422 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497896 | 2.01e-04 |
| 10423 | MESD/NCK2 ratio | GCST90315421 | 2.00e-04 |
| 10424 | CKAP4 levels | GCST90468758 | 2.00e-04 |
| 10425 | Dihexosylceramide (d18:1/24:0) levels | GCST90025349 | 2.00e-04 |
| 10426 | BLOC1S3 levels | GCST90468450 | 1.99e-04 |
| 10427 | Cholesteryl Esters to Total Lipids in Medium LDL percentage | GCST90498747 | 1.99e-04 |
| 10428 | Degree of unsaturation | GCST90502749 | 1.99e-04 |
| 10429 | SLURP1 levels | GCST90470674 | 1.99e-04 |
| 10430 | HippSubfield lh volume Hippocampal-tail | GCST90002668 | 1.99e-04 |
| 10431 | Monounsaturated fatty acid levels | GCST90502362 | 1.98e-04 |
| 10432 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 1.97e-04 |
| 10433 | AMBP/HAVCR1 ratio | GCST90313254 | 1.96e-04 |
| 10434 | CACYBP levels | GCST90468524 | 1.96e-04 |
| 10435 | PRG3 levels | GCST90470323 | 1.96e-04 |
| 10436 | MATN3 levels | GCST90469865 | 1.96e-04 |
| 10437 | CST6 levels | GCST90468896 | 1.95e-04 |
| 10438 | Concentration of very large VLDL particles | GCST90500631 | 1.95e-04 |
| 10439 | Fluid intelligence score decline (difference score) | GCST90565862 | 1.95e-04 |
| 10440 | Phosphatidylcholine (40:8) levels | GCST90025538 | 1.95e-04 |
| 10441 | FCRL2/KLB ratio | GCST90314798 | 1.95e-04 |
| 10442 | Free Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500598 | 1.94e-04 |
| 10443 | HPGDS levels | GCST90469472 | 1.94e-04 |
| 10444 | Serum copper levels | GCST90100524 | 1.94e-04 |
| 10445 | Total Lipids in Medium LDL | GCST90498806 | 1.93e-04 |
| 10446 | CD207 levels | GCST90468607 | 1.93e-04 |
| 10447 | TGFBR2 levels | GCST90470847 | 1.92e-04 |
| 10448 | Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611) | GCST90269708 | 1.92e-04 |
| 10449 | DNMBP/TBC1D5 ratio | GCST90314519 | 1.92e-04 |
| 10450 | Volume of right basal nucleus | GCST90475015 | 1.92e-04 |
| 10451 | FKBP5/MITD1 ratio | GCST90314844 | 1.91e-04 |
| 10452 | Alkylphosphatidylcholine (O-34:1) levels | GCST90024925 | 1.91e-04 |
| 10453 | Nonalcoholic fatty liver disease | GCST90275041 | 1.91e-04 |
| 10454 | Omega-6 fatty acids to total fatty acids percentage | GCST90502127 | 1.91e-04 |
| 10455 | Red blood cell (erythrocyte) count | Blood count | UKBB00000747 | 1.90e-04 |
| 10456 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476343 | 1.90e-04 |
| 10457 | Free Cholesterol in HDL | GCST90497381 | 1.90e-04 |
| 10458 | HBEGF/PDGFA ratio | GCST90315033 | 1.90e-04 |
| 10459 | Mean bone marrow fat fraction of thoracic vertebrae 8-12 | GCST90652385 | 1.90e-04 |
| 10460 | CD300E/CXCL10 ratio | GCST90313796 | 1.90e-04 |
| 10461 | CDCP1 levels | GCST90468667 | 1.89e-04 |
| 10462 | FUT3 or FUT5 levels | GCST90469280 | 1.89e-04 |
| 10463 | Basophil count | GCST90018726 | 1.89e-04 |
| 10464 | LBR levels | GCST90469744 | 1.89e-04 |
| 10465 | Bone marrow fat fraction of lumbar vertebra 2 | GCST90652387 | 1.89e-04 |
| 10466 | X-21364 levels | GCST90200566 | 1.89e-04 |
| 10467 | CSTB levels | GCST90468898 | 1.88e-04 |
| 10468 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T91 | ECGU000091 | 1.88e-04 |
| 10469 | ARHGEF12 levels | GCST90468358 | 1.88e-04 |
| 10470 | CASP3/LYN ratio | GCST90313635 | 1.88e-04 |
| 10471 | FOLR2/THY1 ratio | GCST90314867 | 1.87e-04 |
| 10472 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 1.87e-04 |
| 10473 | Other disorders of breast | FING00001018 | 1.87e-04 |
| 10474 | Total lipids in small HDL (UKB data field 23573) | GCST90269670 | 1.87e-04 |
| 10475 | Phospholipids in small HDL (UKB data field 23574) | GCST90269671 | 1.86e-04 |
| 10476 | GOPC/IRAK4 ratio | GCST90314954 | 1.86e-04 |
| 10477 | SCARA5/TNC ratio | GCST90315810 | 1.86e-04 |
| 10478 | WFDC1 levels | GCST90471074 | 1.85e-04 |
| 10479 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 111) | GCST90320930 | 1.85e-04 |
| 10480 | Left-hemisphere limbic network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302732 | 1.85e-04 |
| 10481 | Sum eosinophil basophil counts | GCST004624 | 1.85e-04 |
| 10482 | RAB6A levels | GCST90470412 | 1.84e-04 |
| 10483 | MARCO/SIGLEC1 ratio | GCST90315387 | 1.84e-04 |
| 10484 | VAV3 levels | GCST90471030 | 1.84e-04 |
| 10485 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T106 | ECGU000106 | 1.84e-04 |
| 10486 | Bioavailable testosterone levels | GCST90012102 | 1.83e-04 |
| 10487 | CLEC1B/HEXIM1 ratio | GCST90314093 | 1.82e-04 |
| 10488 | Platelet count during second trimester of pregnancy | GCST90302225 | 1.82e-04 |
| 10489 | Triacylglycerol_53:3_[M+NH4]1+ levels | GCST90060528 | 1.82e-04 |
| 10490 | ADAMTS8 levels | GCST90468227 | 1.82e-04 |
| 10491 | REST UKBBICA NODEamps25 0001 | GCST90385484 | 1.82e-04 |
| 10492 | Asthma (adult onset) | GCST007799 | 1.81e-04 |
| 10493 | FCER2/TNFRSF9 ratio | GCST90314791 | 1.81e-04 |
| 10494 | NINJ1 levels | GCST90470049 | 1.81e-04 |
| 10495 | Brain glioblastoma, excluding all cancers (controls excluding all cancers) | FING00000225 | 1.80e-04 |
| 10496 | ANGPT2 levels | GCST90468301 | 1.80e-04 |
| 10497 | CA2/NSFL1C ratio | GCST90313580 | 1.79e-04 |
| 10498 | Platelet distribution width (UKB data field 30110) | GCST90468097 | 1.77e-04 |
| 10499 | KLK1 levels | GCST90469702 | 1.77e-04 |
| 10500 | CRISP3 levels | GCST90468866 | 1.76e-04 |
| 10501 | RAB2B levels | GCST90470406 | 1.75e-04 |
| 10502 | ESAM/TNFRSF14 ratio | GCST90314720 | 1.75e-04 |
| 10503 | Concentration of large HDL particles | GCST90497836 | 1.75e-04 |
| 10504 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498689 | 1.75e-04 |
| 10505 | Cholesteryl Esters in Small VLDL | GCST90499782 | 1.75e-04 |
| 10506 | Inflammatory bowel disease | GCST90432182 | 1.74e-04 |
| 10507 | ANPEP levels | GCST90468313 | 1.74e-04 |
| 10508 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T44 | ECGA000044 | 1.74e-04 |
| 10509 | AFM levels | GCST90468249 | 1.74e-04 |
| 10510 | Systolic blood pressure | GCST90472781 | 1.74e-04 |
| 10511 | MSLN levels | GCST90469948 | 1.73e-04 |
| 10512 | PCDH17/TEK ratio | GCST90315606 | 1.73e-04 |
| 10513 | aparc-pial lh area superiorparietal | GCST90003169 | 1.73e-04 |
| 10514 | GAS6 levels | GCST90469305 | 1.72e-04 |
| 10515 | SKAP1 levels | GCST90470645 | 1.72e-04 |
| 10516 | DYNLL1 levels | GCST90240984 | 1.71e-04 |
| 10517 | PPIB levels | GCST90470291 | 1.71e-04 |
| 10518 | T1 FreeSurfer aseg Left-Pallidum | GCST90384146 | 1.70e-04 |
| 10519 | VEGFA levels | GCST90011995 | 1.70e-04 |
| 10520 | CLEC4M levels | GCST90468775 | 1.70e-04 |
| 10521 | LTBR levels | GCST90243176 | 1.70e-04 |
| 10522 | METAP2 levels | GCST90469894 | 1.70e-04 |
| 10523 | Cholesterol esters in very large HDL | GCST90500344 | 1.70e-04 |
| 10524 | CDHR2 levels | GCST90468679 | 1.70e-04 |
| 10525 | NEO1 levels | GCST90470029 | 1.69e-04 |
| 10526 | Hippocampal subfield right CA1 volume (head) | GCST90267961 | 1.69e-04 |
| 10527 | C7 levels | GCST90468502 | 1.69e-04 |
| 10528 | SCARF2/TNFRSF21 ratio | GCST90315813 | 1.69e-04 |
| 10529 | Alkenylphosphatidylethanolamine (P-20:0/18:2) levels | GCST90025683 | 1.68e-04 |
| 10530 | Chronic pancreatitis | GCST90018601 | 1.67e-04 |
| 10531 | Other non-toxic goitre | Disorders of thyroid gland | UKBB00000617 | 1.66e-04 |
| 10532 | VWF levels | GCST90471065 | 1.65e-04 |
| 10533 | Left hippocampal volume (tail) | GCST90267951 | 1.65e-04 |
| 10534 | KIFBP levels | GCST90469683 | 1.65e-04 |
| 10535 | SYAP1 levels | GCST90470792 | 1.65e-04 |
| 10536 | EPS8L2 levels | GCST90469138 | 1.64e-04 |
| 10537 | ATG16L1 levels | GCST90468383 | 1.64e-04 |
| 10538 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T117 | ECGA000117 | 1.64e-04 |
| 10539 | Total fatty acid levels | GCST90502722 | 1.64e-04 |
| 10540 | DNAJB1 levels | GCST90469012 | 1.64e-04 |
| 10541 | Concentration of medium LDL particles | GCST90498819 | 1.63e-04 |
| 10542 | Erythematous conditions (PheCode 695) | GCST90476177 | 1.62e-04 |
| 10543 | Erysipelas | FING00000518 | 1.62e-04 |
| 10544 | AMBP levels | GCST90468288 | 1.62e-04 |
| 10545 | MYDGF levels | GCST90469972 | 1.62e-04 |
| 10546 | OTUD7B levels | GCST90470137 | 1.62e-04 |
| 10547 | FCRL6/KLRD1 ratio | GCST90314807 | 1.62e-04 |
| 10548 | NXPH3 levels | GCST90470112 | 1.61e-04 |
| 10549 | ZFYVE19 levels | GCST90471098 | 1.61e-04 |
| 10550 | TMPRSS11D levels | GCST90470891 | 1.61e-04 |
| 10551 | CD83 levels | GCST90468652 | 1.61e-04 |
| 10552 | CD274 levels | GCST90468613 | 1.60e-04 |
| 10553 | Adhesive capsulitis of shoulder | FING00000043 | 1.59e-04 |
| 10554 | Triglycerides in HDL | GCST90497467 | 1.59e-04 |
| 10555 | FAM3D levels | GCST90469188 | 1.59e-04 |
| 10556 | TNFRSF10B levels | GCST90012021 | 1.58e-04 |
| 10557 | Psoriasis | GCST90468147 | 1.58e-04 |
| 10558 | Docosahexaenoic acid levels | GCST90502258 | 1.58e-04 |
| 10559 | ITGB1BP2/LAT2 ratio | GCST90315212 | 1.57e-04 |
| 10560 | NPPC levels | GCST90470075 | 1.57e-04 |
| 10561 | LRPAP1 levels | GCST90469800 | 1.57e-04 |
| 10562 | TIA1/USP8 ratio | GCST90315920 | 1.57e-04 |
| 10563 | C1R levels | GCST90468493 | 1.56e-04 |
| 10564 | RELT/TNFRSF1A ratio | GCST90315767 | 1.56e-04 |
| 10565 | Clonal haematopoiesis of indeterminate potential (DNMT3A mutation) | GCST90165271 | 1.56e-04 |
| 10566 | CERT levels | GCST90468717 | 1.56e-04 |
| 10567 | GFRAL levels | GCST90469331 | 1.55e-04 |
| 10568 | RNF41/WWP2 ratio | GCST90315782 | 1.55e-04 |
| 10569 | AMOTL2 levels | GCST90468294 | 1.55e-04 |
| 10570 | TGFA levels | GCST90470842 | 1.55e-04 |
| 10571 | PGD levels | GCST90470217 | 1.55e-04 |
| 10572 | CIAPIN1/SNAP29 ratio | GCST90314067 | 1.54e-04 |
| 10573 | Total lipids in very large VLDL | GCST90500614 | 1.54e-04 |
| 10574 | CD55 levels | GCST90468637 | 1.53e-04 |
| 10575 | OMD levels | GCST90470123 | 1.53e-04 |
| 10576 | IGF2R/RNASET2 ratio | GCST90315132 | 1.52e-04 |
| 10577 | MED18/SMAD1 ratio | GCST90315413 | 1.52e-04 |
| 10578 | T1 CAT volume L LeftAccumbens | GCST90384108 | 1.52e-04 |
| 10579 | Triglycerides x anxiety interaction (2df test) | GCST90570677 | 1.51e-04 |
| 10580 | DLK1/RGMB ratio | GCST90314493 | 1.51e-04 |
| 10581 | AFP levels | GCST90468250 | 1.50e-04 |
| 10582 | Platelet count | GCST90002402 | 1.50e-04 |
| 10583 | Omega-3 fatty acid levels | GCST90502064 | 1.50e-04 |
| 10584 | Phospholipids to Total Lipids in Very Large VLDL percentage | GCST90500665 | 1.49e-04 |
| 10585 | CD59/SCARB2 ratio | GCST90313859 | 1.49e-04 |
| 10586 | Provencibacterium abundance in stool | GCST90032528 | 1.49e-04 |
| 10587 | Blood cell traits latent factor 5 (platelet) | GCST90559247 | 1.49e-04 |
| 10588 | Pure hypercholesterolaemia | FING00001230 | 1.49e-04 |
| 10589 | CCL18/TFPI ratio | GCST90313691 | 1.49e-04 |
| 10590 | DTI TBSS L1 External capsule R | GCST90384460 | 1.48e-04 |
| 10591 | CCN2 levels | GCST90468588 | 1.48e-04 |
| 10592 | BCHE levels | GCST90468429 | 1.48e-04 |
| 10593 | ITGB2 levels | GCST90469644 | 1.47e-04 |
| 10594 | Other and unspecified nerve root and plexus disorders, also in other diseases | FING00000944 | 1.47e-04 |
| 10595 | GRAP2/TYMP ratio | GCST90314990 | 1.46e-04 |
| 10596 | DIABLO/MITD1 ratio | GCST90314467 | 1.46e-04 |
| 10597 | CD101 levels | GCST90468596 | 1.46e-04 |
| 10598 | Dorsopathies | FING00000473 | 1.46e-04 |
| 10599 | OSCAR levels | GCST90470131 | 1.46e-04 |
| 10600 | SERPINB6/TXNDC5 ratio | GCST90315832 | 1.45e-04 |
| 10601 | UFD1 levels | GCST90471005 | 1.45e-04 |
| 10602 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500716 | 1.45e-04 |
| 10603 | Progressive vascular leukoencephalopathy | FING00001218 | 1.45e-04 |
| 10604 | X-18922 levels | GCST90200578 | 1.45e-04 |
| 10605 | DNAJA2/FIS1 ratio | GCST90314501 | 1.44e-04 |
| 10606 | Clonal hematopoiesis (large clone) | GCST90102621 | 1.44e-04 |
| 10607 | Blood cell traits latent factor 21 (red cell) | GCST90559263 | 1.44e-04 |
| 10608 | RARRES2/ST6GAL1 ratio | GCST90315759 | 1.43e-04 |
| 10609 | F9/FETUB ratio | GCST90314746 | 1.43e-04 |
| 10610 | FOLR2 levels | GCST90469260 | 1.43e-04 |
| 10611 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502179 | 1.42e-04 |
| 10612 | CC2D1A/STAMBP ratio | GCST90313664 | 1.42e-04 |
| 10613 | ANGPT1/MPIG6B ratio | GCST90313265 | 1.41e-04 |
| 10614 | DNA methylation PhenoAge acceleration | GCST90014292 | 1.41e-04 |
| 10615 | BCR/CLIP2 ratio | GCST90313486 | 1.40e-04 |
| 10616 | PLA2G1B/PRSS2 ratio | GCST90315665 | 1.40e-04 |
| 10617 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 1.40e-04 |
| 10618 | Polyunsaturated fatty acid levels | GCST90502622 | 1.40e-04 |
| 10619 | EFHD1 levels | GCST90469079 | 1.40e-04 |
| 10620 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 1.40e-04 |
| 10621 | Phospholipid levels in small HDL | GCST90092952 | 1.40e-04 |
| 10622 | FKBP14 levels | GCST90469241 | 1.39e-04 |
| 10623 | Autorefraction - 6mm strong meridian angle (right) | Eyesight | UKBB00000078 | 1.39e-04 |
| 10624 | Atherosclerosis, excluding cerebral and coronary sclerosis | FING00000123 | 1.39e-04 |
| 10625 | BA-exvivo lh volume V1 | GCST90002844 | 1.39e-04 |
| 10626 | Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587) | GCST90269684 | 1.38e-04 |
| 10627 | Total cholesterol levels | GCST90500015 | 1.38e-04 |
| 10628 | Cholesterol levels in very large HDL | GCST90500322 | 1.38e-04 |
| 10629 | Illnesses of mother - High blood pressure | Family history | UKBB00000348 | 1.38e-04 |
| 10630 | EREG/MPIG6B ratio | GCST90314704 | 1.37e-04 |
| 10631 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T187 | ECGU000187 | 1.37e-04 |
| 10632 | CD1C levels | GCST90468604 | 1.37e-04 |
| 10633 | LGALS7 or LGALS7B levels | GCST90469763 | 1.37e-04 |
| 10634 | STK11 levels | GCST90470765 | 1.37e-04 |
| 10635 | SPP1 levels | GCST90470733 | 1.36e-04 |
| 10636 | AHSG levels | GCST90468263 | 1.36e-04 |
| 10637 | ACVRL1/TNFRSF10B ratio | GCST90313158 | 1.36e-04 |
| 10638 | C1QTNF9 levels | GCST90468491 | 1.36e-04 |
| 10639 | CFHR5 levels | GCST90468728 | 1.36e-04 |
| 10640 | ANGPTL7 levels | GCST90468306 | 1.35e-04 |
| 10641 | X-21467 levels | GCST90200594 | 1.35e-04 |
| 10642 | Total lipid levels in small HDL | GCST90092950 | 1.35e-04 |
| 10643 | CCDC80 levels | GCST90468562 | 1.35e-04 |
| 10644 | NUCB2/TRIAP1 ratio | GCST90315577 | 1.35e-04 |
| 10645 | ACE2/GGT1 ratio | GCST90313153 | 1.34e-04 |
| 10646 | High light scatter reticulocyte percentage of red cells | GCST004612 | 1.34e-04 |
| 10647 | AIF1 levels | GCST90468267 | 1.34e-04 |
| 10648 | FGFBP1 levels | GCST90469230 | 1.34e-04 |
| 10649 | Lymphocyte count | GCST90002316 | 1.34e-04 |
| 10650 | TNFRSF10B levels | GCST90470900 | 1.33e-04 |
| 10651 | HSPG2/SMOC2 ratio | GCST90315093 | 1.33e-04 |
| 10652 | TNFRSF1B levels | GCST90470911 | 1.33e-04 |
| 10653 | SPINK5 levels | GCST90470724 | 1.33e-04 |
| 10654 | YARS1 levels | GCST90471087 | 1.33e-04 |
| 10655 | Carotid artery plaque burden | GCST90503076 | 1.33e-04 |
| 10656 | F3 levels | GCST90012014 | 1.32e-04 |
| 10657 | INHBC levels | GCST90469615 | 1.32e-04 |
| 10658 | GZMA/LTA ratio | GCST90315012 | 1.32e-04 |
| 10659 | red blood cell count (RBC, minimum, inv-norm transformed) | GCST90476353 | 1.32e-04 |
| 10660 | LAMA4/NID1 ratio | GCST90315272 | 1.31e-04 |
| 10661 | EDAR/ENO2 ratio | GCST90314574 | 1.31e-04 |
| 10662 | Intrinsic epigenetic age acceleration | GCST90014290 | 1.31e-04 |
| 10663 | FGD3 levels | GCST90469217 | 1.30e-04 |
| 10664 | Other cataract | Disorders of lens | UKBB00000602 | 1.29e-04 |
| 10665 | Mean platelet volume | GCST90002395 | 1.29e-04 |
| 10666 | TNFRSF1A levels | GCST90470910 | 1.29e-04 |
| 10667 | Polycystic ovarian syndrome, consortium definition | FING00001184 | 1.29e-04 |
| 10668 | CD22/FOLR2 ratio | GCST90313758 | 1.28e-04 |
| 10669 | Bone marrow fat fraction of lumbar vertebra 3 | GCST90652388 | 1.28e-04 |
| 10670 | Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9) | GCST90475908 | 1.28e-04 |
| 10671 | PRRT3 levels | GCST90470340 | 1.28e-04 |
| 10672 | CA4 levels | GCST90468513 | 1.28e-04 |
| 10673 | Glomerular filtration rate (cystatin C) | GCST003375 | 1.27e-04 |
| 10674 | Total lipids in small HDL | GCST90499443 | 1.27e-04 |
| 10675 | TIA1 levels | GCST90470862 | 1.27e-04 |
| 10676 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T98 | ECGU000098 | 1.27e-04 |
| 10677 | PCSK7 levels | GCST90470176 | 1.27e-04 |
| 10678 | NBL1 levels | GCST90470001 | 1.27e-04 |
| 10679 | ST8SIA1 levels | GCST90470754 | 1.27e-04 |
| 10680 | PACS2 levels | GCST90470141 | 1.27e-04 |
| 10681 | ACVRL1/TNFRSF19 ratio | GCST90313159 | 1.27e-04 |
| 10682 | CHRDL2 levels | GCST90468751 | 1.26e-04 |
| 10683 | IL1RN levels | GCST90469576 | 1.26e-04 |
| 10684 | ARHGAP1 levels | GCST90468352 | 1.26e-04 |
| 10685 | Phosphatidylcholine_34:0_[M+H]1+/Phosphatidylethanolamine_37:0_[M+H]1+/Phosphatidate_39:1_[M+NH4]1+ levels | GCST90060311 | 1.26e-04 |
| 10686 | HippSubfield rh volume CA4-head | GCST90002704 | 1.26e-04 |
| 10687 | SH2B3 levels | GCST90470616 | 1.26e-04 |
| 10688 | Phospholipids to total lipids in small HDL percentage (UKB data field 23644) | GCST90269741 | 1.25e-04 |
| 10689 | Lysophosphatidylcholine (22:6) [sn2] levels | GCST90024185 | 1.25e-04 |
| 10690 | CHRDL1 levels | GCST90468750 | 1.25e-04 |
| 10691 | SPINK2 levels | GCST90470722 | 1.25e-04 |
| 10692 | SMAD1 levels | GCST90470675 | 1.25e-04 |
| 10693 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500695 | 1.25e-04 |
| 10694 | CSF1/IL10RB ratio | GCST90314284 | 1.24e-04 |
| 10695 | Triacylglycerol_54:5_[M+NH4]1+ levels | GCST90060539 | 1.24e-04 |
| 10696 | HAVCR2/TNFRSF1B ratio | GCST90315030 | 1.23e-04 |
| 10697 | PCDH17 levels | GCST90470169 | 1.23e-04 |
| 10698 | SEPTIN3 levels | GCST90470576 | 1.23e-04 |
| 10699 | IDP dMRI ProbtrackX OD fmi | GCST90004461 | 1.23e-04 |
| 10700 | WASF1 levels | GCST90471067 | 1.23e-04 |
| 10701 | CASP8/PPP3R1 ratio | GCST90313654 | 1.23e-04 |
| 10702 | Calcific aortic valve stenosis | GCST90310293 | 1.23e-04 |
| 10703 | Waist-hip index | GCST90020027 | 1.23e-04 |
| 10704 | Monocyte count | GCST90002393 | 1.23e-04 |
| 10705 | CLEC4D/MANSC1 ratio | GCST90314112 | 1.23e-04 |
| 10706 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 1.22e-04 |
| 10707 | CCN5 levels | GCST90468591 | 1.22e-04 |
| 10708 | Lymphocyte count | GCST90025984 | 1.22e-04 |
| 10709 | Myocardial infarction (PheCode 411.2) | GCST90475932 | 1.22e-04 |
| 10710 | Platelet distribution width | GCST90002401 | 1.22e-04 |
| 10711 | ACE2 levels | GCST90468197 | 1.22e-04 |
| 10712 | IL3RA levels | GCST90469596 | 1.21e-04 |
| 10713 | CLEC1B/GP1BA ratio | GCST90314091 | 1.21e-04 |
| 10714 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 108) | GCST90320671 | 1.21e-04 |
| 10715 | DTI autoptx MD str r tract | GCST90385244 | 1.21e-04 |
| 10716 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501031 | 1.21e-04 |
| 10717 | monocyte (absolute count, maximum, inv-norm transformed) | GCST90475499 | 1.21e-04 |
| 10718 | Mean bone marrow fat fraction of lumbar vertebrae 1-5 | GCST90652391 | 1.20e-04 |
| 10719 | CD5 levels | GCST90468641 | 1.20e-04 |
| 10720 | LY6D/WFDC12 ratio | GCST90315346 | 1.20e-04 |
| 10721 | X-12707 levels | GCST90200502 | 1.20e-04 |
| 10722 | Asthma/COPD (KELA code 203) | FING00000121 | 1.20e-04 |
| 10723 | TST levels | GCST90470982 | 1.19e-04 |
| 10724 | NCK2/PLA2G4A ratio | GCST90315524 | 1.19e-04 |
| 10725 | BA-exvivo lh area BA6 | GCST90003213 | 1.19e-04 |
| 10726 | Monocyte percentage | Blood count | UKBB00000480 | 1.19e-04 |
| 10727 | ADGRE2/CD58 ratio | GCST90313175 | 1.19e-04 |
| 10728 | HMCN2 levels | GCST90469461 | 1.19e-04 |
| 10729 | Sphingomyelin_36:1_[M+H]1+ levels | GCST90060266 | 1.19e-04 |
| 10730 | TRIM25 levels | GCST90470966 | 1.18e-04 |
| 10731 | Waist-to-hip ratio adjusted for BMI | GCST90020025 | 1.18e-04 |
| 10732 | Reticulocyte fraction of red cells | GCST90002406 | 1.18e-04 |
| 10733 | Fracture of forearm | FING00000554 | 1.18e-04 |
| 10734 | LCP1 levels | GCST90469748 | 1.18e-04 |
| 10735 | Inguinal hernia | GCST90018648 | 1.17e-04 |
| 10736 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T122 | ECGU000122 | 1.17e-04 |
| 10737 | A body shape index | GCST012231 | 1.17e-04 |
| 10738 | Cholesteryl Esters in VLDL | GCST90500211 | 1.17e-04 |
| 10739 | SMAD2 levels | GCST90470676 | 1.17e-04 |
| 10740 | THBD levels | GCST90470853 | 1.17e-04 |
| 10741 | NME3 levels | GCST90470055 | 1.16e-04 |
| 10742 | Triglycerides in VLDL | GCST90500304 | 1.16e-04 |
| 10743 | CXADR/GGT1 ratio | GCST90314328 | 1.16e-04 |
| 10744 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502075 | 1.16e-04 |
| 10745 | Red blood cell count | GCST90002364 | 1.15e-04 |
| 10746 | Heart rate variability (standard deviation of normal-to-normal intervals) | GCST90281265 | 1.15e-04 |
| 10747 | Platelet count | Blood count | UKBB00000646 | 1.15e-04 |
| 10748 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T57 | ECGA000057 | 1.15e-04 |
| 10749 | Left-hemisphere control network to caudate white-matter structural connectivity | GCST90302753 | 1.15e-04 |
| 10750 | Syncope and collapse | symptoms | UKBB00000801 | 1.15e-04 |
| 10751 | PVALB levels | GCST90470393 | 1.14e-04 |
| 10752 | Takes medication for prostate cancer? | GCST90475187 | 1.14e-04 |
| 10753 | FOLR2/MSR1 ratio | GCST90314866 | 1.14e-04 |
| 10754 | Heart valve replaced (PheCode 395.6) | GCST90475915 | 1.14e-04 |
| 10755 | PIK3IP1 levels | GCST90470234 | 1.14e-04 |
| 10756 | ANGPT1/PDGFA ratio | GCST90313266 | 1.14e-04 |
| 10757 | CCL22/PDGFB ratio | GCST90313692 | 1.14e-04 |
| 10758 | Otitis externa | FING00001128 | 1.13e-04 |
| 10759 | CA4/FOLR2 ratio | GCST90313585 | 1.13e-04 |
| 10760 | DDAH1 levels | GCST90468966 | 1.13e-04 |
| 10761 | ICD10 N84: Polyp of female genital tract | GCST90454216 | 1.13e-04 |
| 10762 | Left-hemisphere control network to pallidum white-matter structural connectivity | GCST90302755 | 1.13e-04 |
| 10763 | ITGB1/MCAM ratio | GCST90315226 | 1.13e-04 |
| 10764 | Diarrhoea and gastroenteritis of presumed infectious origin | FING00000420 | 1.13e-04 |
| 10765 | ARHGEF5 levels | GCST90468360 | 1.13e-04 |
| 10766 | LY96 levels | GCST90469823 | 1.12e-04 |
| 10767 | DOK2 levels | GCST90469029 | 1.12e-04 |
| 10768 | PPP1R2 levels | GCST90470304 | 1.12e-04 |
| 10769 | GP6 levels | GCST90469384 | 1.11e-04 |
| 10770 | ALPP/LAMP3 ratio | GCST90313249 | 1.11e-04 |
| 10771 | Height decline (difference score) | GCST90565863 | 1.10e-04 |
| 10772 | Monocyte count | Blood count | UKBB00000479 | 1.10e-04 |
| 10773 | ESAM/SORT1 ratio | GCST90314716 | 1.10e-04 |
| 10774 | MITD1 levels | GCST90469910 | 1.10e-04 |
| 10775 | NUDT16 levels | GCST90470105 | 1.10e-04 |
| 10776 | COLEC12/NBL1 ratio | GCST90314183 | 1.09e-04 |
| 10777 | platelet count (mean, inv-norm transformed) | GCST90476299 | 1.09e-04 |
| 10778 | COLEC12 levels | GCST90468824 | 1.09e-04 |
| 10779 | WARS levels | GCST90471066 | 1.09e-04 |
| 10780 | FOXO1/USP8 ratio | GCST90314879 | 1.09e-04 |
| 10781 | PRTG levels | GCST90470347 | 1.09e-04 |
| 10782 | Triacylglycerol_54:7_[M+NH4]1+ levels | GCST90060536 | 1.09e-04 |
| 10783 | TNFRSF21 levels | GCST90470912 | 1.08e-04 |
| 10784 | Triacylglycerol (48:2) [NL-16:0] levels | GCST90025143 | 1.08e-04 |
| 10785 | APP/BIN2 ratio | GCST90313316 | 1.08e-04 |
| 10786 | DIABLO/PRKAR1A ratio | GCST90314469 | 1.08e-04 |
| 10787 | Bone marrow fat fraction of thoracic vertebra 10 | GCST90652382 | 1.07e-04 |
| 10788 | PLA2G7 levels | GCST90470249 | 1.07e-04 |
| 10789 | ATP5IF1 levels | GCST90468392 | 1.07e-04 |
| 10790 | DAG1/PDGFA ratio | GCST90314378 | 1.07e-04 |
| 10791 | BACH1/SNAP23 ratio | GCST90313446 | 1.06e-04 |
| 10792 | MCFD2/VSIR ratio | GCST90315411 | 1.06e-04 |
| 10793 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T139 | ECGU000139 | 1.06e-04 |
| 10794 | VASH1 levels | GCST90471026 | 1.06e-04 |
| 10795 | HSPB1/PLIN3 ratio | GCST90315088 | 1.06e-04 |
| 10796 | CD69/TIA1 ratio | GCST90313888 | 1.06e-04 |
| 10797 | Bone marrow fat fraction of lumbar vertebra 5 | GCST90652390 | 1.06e-04 |
| 10798 | FLI1 levels | GCST90469247 | 1.05e-04 |
| 10799 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T54 | ECGA000054 | 1.05e-04 |
| 10800 | KLK6 levels | GCST90469705 | 1.05e-04 |
| 10801 | IL18 levels | GCST90469567 | 1.05e-04 |
| 10802 | CXCL12 levels | GCST90468925 | 1.05e-04 |
| 10803 | LYN/SIRT2 ratio | GCST90315349 | 1.05e-04 |
| 10804 | Monocyte count (UKB data field 30130) | GCST90468090 | 1.05e-04 |
| 10805 | Enthesopathy (PheCode 726.1) | GCST90476239 | 1.05e-04 |
| 10806 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 1.05e-04 |
| 10807 | CD5/IL16 ratio | GCST90313861 | 1.04e-04 |
| 10808 | CDSN/NECTIN4 ratio | GCST90313998 | 1.04e-04 |
| 10809 | APOB/APOA1 ratio | GCST90497156 | 1.03e-04 |
| 10810 | NECTIN2/SDC1 ratio | GCST90315529 | 1.03e-04 |
| 10811 | HEG1 levels | GCST90469444 | 1.03e-04 |
| 10812 | FCAMR levels | GCST90469196 | 1.03e-04 |
| 10813 | Abdominal aortic aneurysm (AAA) | FING00000001 | 1.03e-04 |
| 10814 | BIN2/PDLIM7 ratio | GCST90313509 | 1.02e-04 |
| 10815 | ANGPT1/CCN2 ratio | GCST90313261 | 1.02e-04 |
| 10816 | IL7R levels | GCST90469605 | 1.02e-04 |
| 10817 | GBP1 levels | GCST90469311 | 1.01e-04 |
| 10818 | DRAXIN levels | GCST90469038 | 1.01e-04 |
| 10819 | CD6/EZR ratio | GCST90313890 | 1.01e-04 |
| 10820 | Right ventricular ejection fraction (MTAG) | GCST90134595 | 1.01e-04 |
| 10821 | Urea levels (UKB data field 30670) | GCST90468108 | 1.00e-04 |
| 10822 | CD302/IL12A_IL12B ratio | GCST90313806 | 1.00e-04 |
| 10823 | KLK8 levels | GCST90469707 | 1.00e-04 |
| 10824 | C19ORF12 levels | GCST90468483 | 9.96e-05 |
| 10825 | Pulse pressure (BMI adjusted) | GCST90335167 | 9.95e-05 |
| 10826 | PZP levels | GCST90470399 | 9.94e-05 |
| 10827 | GOLM2/ITGA5 ratio | GCST90314951 | 9.93e-05 |
| 10828 | FBP1 levels | GCST90469195 | 9.93e-05 |
| 10829 | HippSubfield rh volume presubiculum-head | GCST90002695 | 9.91e-05 |
| 10830 | PDGFB/USP8 ratio | GCST90315633 | 9.79e-05 |
| 10831 | HSIL lesion of the cervix uteri | FING00000624 | 9.79e-05 |
| 10832 | DTI autoptx FA ilf r tract | GCST90385127 | 9.76e-05 |
| 10833 | IDP dMRI TBSS L3 Uncinate fasciculus R | GCST90004215 | 9.75e-05 |
| 10834 | COLEC12/TGFBR2 ratio | GCST90314186 | 9.75e-05 |
| 10835 | Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586) | GCST90269683 | 9.75e-05 |
| 10836 | CDKN2D levels | GCST90468685 | 9.74e-05 |
| 10837 | aparc-Desikan lh volume pericalcarine | GCST90002788 | 9.71e-05 |
| 10838 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 9.70e-05 |
| 10839 | MIA levels | GCST90469903 | 9.70e-05 |
| 10840 | CRYZL1 levels | GCST90468878 | 9.70e-05 |
| 10841 | CANT1/GSTA1 ratio | GCST90313616 | 9.69e-05 |
| 10842 | EREG/F2R ratio | GCST90314700 | 9.67e-05 |
| 10843 | SNX18 levels | GCST90470700 | 9.64e-05 |
| 10844 | TNIP1 levels | GCST90470925 | 9.63e-05 |
| 10845 | IL31RA levels | GCST90469589 | 9.63e-05 |
| 10846 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502168 | 9.60e-05 |
| 10847 | FRZB levels | GCST90469269 | 9.59e-05 |
| 10848 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T58 | ECGA000058 | 9.57e-05 |
| 10849 | Omega-3 fatty acid levels | GCST90502062 | 9.55e-05 |
| 10850 | MAP2K6/TBL1X ratio | GCST90315378 | 9.49e-05 |
| 10851 | Blood cell traits latent factor 6 (red cell (and basophil)) | GCST90559248 | 9.49e-05 |
| 10852 | AKT1S1 levels | GCST90468276 | 9.48e-05 |
| 10853 | CASP2 levels | GCST90468544 | 9.47e-05 |
| 10854 | MAVS/MYO9B ratio | GCST90315390 | 9.46e-05 |
| 10855 | Osteoporosis, osteopenia and pathological fracture | musculoskeletal | UKBB00000600 | 9.45e-05 |
| 10856 | FKBP4/WWP2 ratio | GCST90314842 | 9.44e-05 |
| 10857 | CA5A/GRPEL1 ratio | GCST90313590 | 9.43e-05 |
| 10858 | SPARCL1 levels | GCST90470717 | 9.43e-05 |
| 10859 | DAB2/TBL1X ratio | GCST90314368 | 9.42e-05 |
| 10860 | Blood cell traits latent factor 7 (white cell) | GCST90559249 | 9.41e-05 |
| 10861 | SDC4/SERPINE1 ratio | GCST90315819 | 9.39e-05 |
| 10862 | APP/TMSB10 ratio | GCST90313332 | 9.39e-05 |
| 10863 | IGSF8/VSIR ratio | GCST90315141 | 9.37e-05 |
| 10864 | MEP1A levels | GCST90469887 | 9.36e-05 |
| 10865 | SERPINE1/USP8 ratio | GCST90315835 | 9.36e-05 |
| 10866 | PRG2 levels | GCST90470322 | 9.35e-05 |
| 10867 | Mean diameter of VLDL particles | GCST90132734 | 9.32e-05 |
| 10868 | BACH1 levels | GCST90468415 | 9.29e-05 |
| 10869 | MAPKAPK2 levels | GCST90469858 | 9.27e-05 |
| 10870 | CDA levels | GCST90468660 | 9.24e-05 |
| 10871 | Cholesteryl Esters in HDL | GCST90497368 | 9.18e-05 |
| 10872 | CD79B/FCRL1 ratio | GCST90313899 | 9.16e-05 |
| 10873 | MAVS/SCAMP3 ratio | GCST90315396 | 9.15e-05 |
| 10874 | EDAR/F11R ratio | GCST90314576 | 9.14e-05 |
| 10875 | Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453) | GCST90269550 | 9.09e-05 |
| 10876 | HSPG2 levels | GCST90469491 | 9.08e-05 |
| 10877 | DTI TBSS MD Anterior corona radiata R | GCST90384594 | 9.08e-05 |
| 10878 | Plateletcrit | GCST004607 | 9.06e-05 |
| 10879 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502593 | 9.03e-05 |
| 10880 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502410 | 9.01e-05 |
| 10881 | LAMP3 levels | GCST90469735 | 8.99e-05 |
| 10882 | TBCC levels | GCST90470814 | 8.96e-05 |
| 10883 | IL15/KLRD1 ratio | GCST90315149 | 8.96e-05 |
| 10884 | Fractures | GCST006980 | 8.96e-05 |
| 10885 | EFCAB14 levels | GCST90469076 | 8.93e-05 |
| 10886 | LMOD1 levels | GCST90469783 | 8.93e-05 |
| 10887 | KLRD1 levels | GCST90469711 | 8.93e-05 |
| 10888 | Succinylcarnitine levels | GCST90243874 | 8.91e-05 |
| 10889 | RABEP1 levels | GCST90470414 | 8.91e-05 |
| 10890 | GZMA/TNFRSF4 ratio | GCST90315013 | 8.86e-05 |
| 10891 | Phospholipids in large VLDL | GCST90498247 | 8.86e-05 |
| 10892 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 8.86e-05 |
| 10893 | CKB levels | GCST90468759 | 8.85e-05 |
| 10894 | EBI3_IL27/VCAM1 ratio | GCST90314572 | 8.84e-05 |
| 10895 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T105 | ECGA000105 | 8.82e-05 |
| 10896 | Lymphocyte count | Blood count | UKBB00000411 | 8.80e-05 |
| 10897 | PDGFA/SCARF1 ratio | GCST90315617 | 8.79e-05 |
| 10898 | PCDH17/PTPRM ratio | GCST90315603 | 8.77e-05 |
| 10899 | LRRC59 levels | GCST90469804 | 8.77e-05 |
| 10900 | WIF1 levels | GCST90471078 | 8.76e-05 |
| 10901 | Myocardial fractal dimension (slice 5) | GCST90000291 | 8.76e-05 |
| 10902 | Peripheral vascular disease, unspecified (PheCode 443.9) | GCST90475998 | 8.75e-05 |
| 10903 | Arthropathies | FING00000107 | 8.73e-05 |
| 10904 | Ulcerative colitis | GCST90018713 | 8.72e-05 |
| 10905 | HippSubfield lh volume Whole-hippocampus | GCST90002689 | 8.70e-05 |
| 10906 | Monocyte count | GCST90025950 | 8.67e-05 |
| 10907 | CD80 levels | GCST90468650 | 8.66e-05 |
| 10908 | Heart rate variability (corrected standard deviation of normal-to-normal intervals) | GCST90281266 | 8.64e-05 |
| 10909 | EDA2R levels | GCST90469067 | 8.61e-05 |
| 10910 | NCAN levels | GCST90618559 | 8.61e-05 |
| 10911 | CST7 levels | GCST90468897 | 8.59e-05 |
| 10912 | FHIT/GLOD4 ratio | GCST90314817 | 8.58e-05 |
| 10913 | Omega-6 fatty acids to total fatty acids percentage | GCST90502529 | 8.58e-05 |
| 10914 | IL1RN levels | GCST90012004 | 8.58e-05 |
| 10915 | Shoulder lesions | Other soft tissue disorders | UKBB00000769 | 8.57e-05 |
| 10916 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500754 | 8.57e-05 |
| 10917 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498682 | 8.54e-05 |
| 10918 | PDCD1 levels | GCST90470181 | 8.51e-05 |
| 10919 | Omega-3 fatty acids to total fatty acids percentage | GCST90502449 | 8.49e-05 |
| 10920 | SERPING1 levels | GCST90470600 | 8.48e-05 |
| 10921 | CCL18/RARRES2 ratio | GCST90313690 | 8.48e-05 |
| 10922 | Cholesterol in Medium LDL | GCST90498707 | 8.47e-05 |
| 10923 | Triglycerides to total lipids ratio in large VLDL | GCST90092879 | 8.46e-05 |
| 10924 | EDAR/ITGB1BP2 ratio | GCST90314580 | 8.41e-05 |
| 10925 | F3 levels | GCST90469170 | 8.38e-05 |
| 10926 | GP6/TMSB10 ratio | GCST90314975 | 8.36e-05 |
| 10927 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 43) | GCST90320606 | 8.36e-05 |
| 10928 | DTI autoptx MD ifo l tract | GCST90385232 | 8.35e-05 |
| 10929 | IL10RB levels | GCST90469545 | 8.33e-05 |
| 10930 | DTI TBSS L2 Fornix | GCST90384481 | 8.33e-05 |
| 10931 | ADA2/VCAM1 ratio | GCST90313167 | 8.31e-05 |
| 10932 | APRT/NSFL1C ratio | GCST90313337 | 8.29e-05 |
| 10933 | monocyte (fraction, mean, inv-norm transformed) | GCST90475511 | 8.28e-05 |
| 10934 | LCN2/S100A12 ratio | GCST90315309 | 8.27e-05 |
| 10935 | Saturated fatty acids to total fatty acids percentage | GCST90502205 | 8.25e-05 |
| 10936 | aparc-Desikan lh area superiorparietal | GCST90003101 | 8.25e-05 |
| 10937 | FUT8 levels | GCST90469281 | 8.24e-05 |
| 10938 | TMSB10 levels | GCST90470894 | 8.24e-05 |
| 10939 | Percentage of M9 (GP18) | GCST90668696 | 8.24e-05 |
| 10940 | EDAR/EGF ratio | GCST90314573 | 8.23e-05 |
| 10941 | IL1RL1 levels | GCST90469574 | 8.19e-05 |
| 10942 | Total Alkenylphosphatidylcholine levels | GCST90025835 | 8.19e-05 |
| 10943 | CD300C/NBL1 ratio | GCST90313792 | 8.18e-05 |
| 10944 | LRRC25 levels | GCST90469801 | 8.17e-05 |
| 10945 | KIAA2013 levels | GCST90469679 | 8.16e-05 |
| 10946 | ITGAM/ITGAV ratio | GCST90315209 | 8.15e-05 |
| 10947 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502398 | 8.13e-05 |
| 10948 | CD27 levels | GCST90468615 | 8.08e-05 |
| 10949 | SNAP23/TBL1X ratio | GCST90315856 | 8.07e-05 |
| 10950 | DNA methylation Hannum age acceleration | GCST90014289 | 8.07e-05 |
| 10951 | Alkylphosphatidylcholine (O-34:1) levels | GCST90025551 | 8.04e-05 |
| 10952 | CALCOCO1/METAP2 ratio | GCST90313606 | 8.02e-05 |
| 10953 | CD36 levels | GCST90468627 | 8.01e-05 |
| 10954 | Spondylosis | FING00001327 | 7.99e-05 |
| 10955 | Triglycerides in large LDL | GCST90498083 | 7.99e-05 |
| 10956 | CLEC4G levels | GCST90468774 | 7.99e-05 |
| 10957 | NFATC3 levels | GCST90470034 | 7.99e-05 |
| 10958 | EPHA1 levels | GCST90469129 | 7.99e-05 |
| 10959 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 54) | GCST90320873 | 7.95e-05 |
| 10960 | ITGB1BP2 levels | GCST90469642 | 7.93e-05 |
| 10961 | GSTA1/PBLD ratio | GCST90314994 | 7.93e-05 |
| 10962 | FOXJ3 levels | GCST90469264 | 7.92e-05 |
| 10963 | Mean platelet (thrombocyte) volume | Blood count | UKBB00000450 | 7.91e-05 |
| 10964 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502077 | 7.89e-05 |
| 10965 | FAM3C levels | GCST90469187 | 7.88e-05 |
| 10966 | platelet count (maximum, inv-norm transformed) | GCST90476296 | 7.83e-05 |
| 10967 | Gout | FING00000587 | 7.82e-05 |
| 10968 | DLL1 levels | GCST90469004 | 7.82e-05 |
| 10969 | Ulcerative colitis | GCST90446795 | 7.80e-05 |
| 10970 | PTPN6/YES1 ratio | GCST90315750 | 7.78e-05 |
| 10971 | NIT1 levels | GCST90470050 | 7.78e-05 |
| 10972 | MINK1 levels | GCST90469909 | 7.76e-05 |
| 10973 | Tonsillectomy and adenotomy | FING00001367 | 7.76e-05 |
| 10974 | KLK8 levels | GCST90241680 | 7.76e-05 |
| 10975 | IL6ST/MARCO ratio | GCST90315167 | 7.75e-05 |
| 10976 | PTPRK levels | GCST90470383 | 7.75e-05 |
| 10977 | monocyte (absolute count, mean, inv-norm transformed) | GCST90475502 | 7.74e-05 |
| 10978 | Left ventricular outflow tract obstruction (LVOTO), broad definition | FING00000717 | 7.73e-05 |
| 10979 | Platelet count | GCST004603 | 7.72e-05 |
| 10980 | MEGF9/MET ratio | GCST90315418 | 7.71e-05 |
| 10981 | KLRD1/LY9 ratio | GCST90315261 | 7.70e-05 |
| 10982 | TRIM21 levels | GCST90470964 | 7.69e-05 |
| 10983 | STX16 levels | GCST90470769 | 7.67e-05 |
| 10984 | ALB/Globulin ratio | UKBB00000020 | 7.67e-05 |
| 10985 | P4HB levels | GCST90470140 | 7.64e-05 |
| 10986 | PTPN1/TDRKH ratio | GCST90315745 | 7.63e-05 |
| 10987 | IDP dMRI TBSS L2 Sagittal stratum L | GCST90004154 | 7.63e-05 |
| 10988 | Insomnia complaints | GCST006488 | 7.62e-05 |
| 10989 | ALB levels | GCST90092807 | 7.60e-05 |
| 10990 | Triglycerides to Total Lipids in Small HDL percentage | GCST90499530 | 7.57e-05 |
| 10991 | CFI levels | GCST90240782 | 7.57e-05 |
| 10992 | SDCCAG8 levels | GCST90470560 | 7.55e-05 |
| 10993 | Facial ageing | Sun exposure | UKBB00000233 | 7.51e-05 |
| 10994 | CCL21 levels | GCST90468573 | 7.45e-05 |
| 10995 | ESAM/PDGFB ratio | GCST90314714 | 7.45e-05 |
| 10996 | neutrophil (absolute count, minimum, inv-norm transformed) | GCST90475532 | 7.43e-05 |
| 10997 | aseg rh number HolesBeforeFixing | GCST90002647 | 7.43e-05 |
| 10998 | CSPG4 levels | GCST90468890 | 7.41e-05 |
| 10999 | REG1B/REG3A ratio | GCST90315765 | 7.40e-05 |
| 11000 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T493 | ECGU000493 | 7.40e-05 |